title: The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies.
abstract: OBJECTIVE
  To assess the effects of a gonadotropin-releasing hormone agonist (GnRH-a) depot (Leuprolide acetate) in women with gynecologic cancer receiving chemotherapy while taking a continuous add-back on the prevention of premature ovarian failure.
  
  
  METHODS
  Fourteen premenopausal patients with gynecological malignancies who had undergone conservation of ovaries surgery received a GnRH-a depot plus add-back until chemotherapy was completed. Four weeks thereafter, a hormonal profile (follicle stimulating hormone) was measured.
  
  
  RESULTS
  The mean follicle stimulating hormone level was 15.8 IU/L. All patients exhibited a restoration of ovarian failure during follow-up. One patient became pregnant during the follow-up period.
  
  
  CONCLUSIONS
  In the short term, GnRH-a appears to protect ovarian function and ability to achieve pregnancy following chemotherapy. The result of our study needs further elucidation in a large randomized controlled trial.
authors.affiliation: Department of Obstetrics and Gynecology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea.
authors.forename: Chan-Yong
authors.initials: CY
authors.lastname: Park
authors.affiliation: Department of Obstetrics and Gynecology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea.
authors.forename: Sun-Young
authors.initials: SY
authors.lastname: Jung
authors.affiliation: Department of Obstetrics and Gynecology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea.
authors.forename: Kwang-Beom
authors.initials: KB
authors.lastname: Lee
authors.affiliation: Department of Obstetrics and Gynecology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea.
authors.forename: Sun-Hye
authors.initials: SH
authors.lastname: Yang
keywords: Adjuvant chemotherapy; Fertility preservation; Gonadotropin releasing hormone agonist; Ovarian neoplasms; Uterine cervical neoplasms